Fig 2: FGF15 levels and intestinal damage before procurement from DCDs. (A) FGF15 levels in liver and liver injury and regeneration parameters. (B) FGF15 in plasma and intestine and MDA and MPO in intestine. * p < 0.05 vs. Sham; + p < 0.05 vs. CD.

Fig 3: FGF15 levels and intestinal damage in LT with DCDs. (A) FGF15 protein expression in liver, intestine, and plasma. (B) Intestinal injury parameters: MDA, MPO and histological injury according to Chiu-score. * p < 0.05 vs. Sham; + P < 0.05 vs. LT.

Fig 4: Effect of FGF15 on Hippo/YAP signaling pathway in LT with DCDs. (A) mRNA expression of Mst1, Lats1, and protein levels of LATS, p-LATS, and p-LATS/LATS ratio in liver. (B) mRNA levels of Yap, protein levels of YAP, p-YAP, p-YAP/YAP ratio; mRNA expression levels of Ctgf and Iqgap1 in liver. * p < 0.05 v.s Sham and + p < 0.05 vs. LT; # p < 0.05 vs. CD + LT. (C) Representative photomicrographs of YAP immunohistochemical positivity. Inmunostaining of cytoplasmatic YAP in hepatocyte (thick arrow) of LT group and YAP nuclear staining in CD + LT and CD + FGF15Inh + LT groups (thin arrow) (40×).